To the Editor, A Multicenter, Open-Label, Early Access Treatment Protocol for Ibrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Journal of oncology pharmacy practice（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined